A5051959034- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Retinoids in leukemia and cellular processes
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
- Drug Transport and Resistance Mechanisms
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
- Platelet Disorders and Treatments
- Lung Cancer Research Studies
- Complement system in diseases
- Urticaria and Related Conditions
- Protein Degradation and Inhibitors
- Organ and Tissue Transplantation Research
- Advanced Breast Cancer Therapies
Örebro University
2014-2025
Örebro University Hospital
2011-2023
Hudson Institute
2020
John Wiley & Sons (United States)
2020
Boston University
2019
Seattle University
2019
Leukemia Research Foundation
2014
Sahlgrenska University Hospital
2012
Uppsala University Hospital
2012
Karolinska University Hospital
2006-2012
Purpose APR-246 (PRIMA-1MET) is a novel drug that restores transcriptional activity of unfolded wild-type or mutant p53. The main aims this first-in-human trial were to determine maximum-tolerated dose (MTD), safety, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) APR-246. Patients Methods was administered as 2-hour intravenous infusion once per day for 4 consecutive days in 22 patients with hematologic malignancies prostate cancer. Acute myeloid leukemia (AML; n = 7) cancer (n...
Patients with secondary acute myeloid leukemia (AML) often escape inclusion in clinical trials and thus, population‐based studies are crucial for its accurate characterization. In this first large study on AML, we studied AML an antecedent hematological disease (AHD‐AML) or therapy‐related (t‐AML) the Swedish Acute Leukemia Registry. The included 3,363 adult patients of which 2,474 (73.6%) had de novo 630 (18.7%) AHD‐AML, 259 (7.7%) t‐AML. Secondary differed significantly compared to respect...
<h3>Background</h3> Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic sustained follow-up treated patients constitute important information about safety efficacy. In this observational study, we describe the characteristics outcome Swedish with HSCT MS. <h3>Methods</h3> Neurologists major hospitals in Sweden filled out form...
A plastic anemia is a rare life-threatening disease. However, since the introduction of immunosuppressive therapy and allogeneic stem cell transplantation, outcome has improved considerably, 5-year survival reported to be 70–80% in selected patient cohorts. Yet, contemporary population-based data on incidence are lacking. We performed national retrospective study determine incidence, treatment, patients with aplastic diagnosed Sweden from 2000–2011. Patients were included via National...
The Swedish population-based acute myeloid leukemia registry contains data from 3251 patients (excluding promyelocytic leukemia) diagnosed between 1997 and 2006. Informative cytogenetic 1893 were retrospectively added, including 1054 aged 60 79 years. Clonal abnormalities found in 57% of the informative karyotypes. Karyotypic patterns differed by age: t(8;21), inv(16) t(11q23) more common younger patients, whereas loss 5q, 7q 17p, monosomal karyotype (MK) complex karyotypes older patients....
With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, high-risk of ED must be identified. Our aim was to develop a score that predicts risk real-life setting. We used APL populationbased Swedish AML Registry (n=301) and Portuguese hospital-based registry (n=129) as training validation cohorts, respectively. The cohorts were comparable respect age (median, 54...
Patients with chronic lymphocytic leukemia (CLL) have impaired response to vaccination, which calls for improved vaccination strategies. This study aimed evaluate antibody persistence five years after pneumococcal and revaccination. Seventyfour CLL patients 31 controls, all primary immunized 13-valent conjugated vaccine (PCV13) or 23-valent polysaccharide (PPSV23), were included. Antibody was assessed, followed by revaccination PCV13 a second PPSV23. Serological protection (SP), defined as...
To ascertain the clinical implications of high hyperdiploid (HH; 49–65 chromosomes) and triploid/tetraploid (TT; >65 adult acute myeloid leukemia (AML), all such cases were retrieved from Swedish AML Registry. Of 3,654 cytogenetically informative diagnosed between January 1997 May 2014, 68 (1.9%) HH ( n = 50)/TT 18). Patients with HH/TT older than those intermediate risk (IR) (median 71 years vs. 67 years; P 0.042) less often had de novo (63% 79%; 0.004); no differences observed complex...
Acute myeloid leukemia (AML) with t(9;22)(q34;q11), also known as AML BCR-ABL1, is a rare, provisional entity in the WHO 2016 classification and considered high-risk disease according to European LeukemiaNet 2017 risk stratification. We here present retrospective, population-based study of this from Swedish Leukemia Registry. By strict clinical inclusion criteria we aimed identify genetic markers further distinguishing t(9;22) separate entity. Twenty-five patients were identified...
Unsuccessful cytogenetics (UC) in patients with acute myeloid leukaemia (AML) treated on different SWOG trials was recently reported to be associated increased age and dismal outcome. To ascertain whether this holds true also unselected AML, we retrieved all cytogenetic reports cases from the population-based Swedish AML Registry. Between 1997 2006, 1737 below 80 yr of without myelosarcoma or promyelocytic received intensive treatment. The frequencies UC unperformed (UPC) were 2.1% 20%,...
Abstract Objectives Antithymocyte globulin ( ATG )‐based immunosuppression remains a cornerstone in aplastic anaemia AA ) treatment. However, most studies are not population‐based and knowledge about real‐world results concerning response outcome could offer important information for treating physicians. Methods We have recently performed nationwide retrospective cohort study on all patients diagnosed Sweden 2000–2011 now present treatment data receiving first‐line . In total, 158 showed...
Abstract Objectives and Methods To ascertain the incidence/clinical implications of isolated autosomal trisomies in adult acute myeloid leukemia (AML), all such cases were retrieved from Swedish AML Registry. Results Of 3179 cytogenetically informative AMLs diagnosed January 1997‐May 2015, 246 (7.7%) had trisomies. The frequency increased by age (2.4% at 18‐60 years vs. 23% >60 years; P <.0001); median was 69 years. five most common +8 (4.0%), +13 (0.9%), +11 (0.8%), +21 (0.7%), +4...
Allogeneic stem cell transplantation (SCT) as primary treatment for aplastic anemia (AA) is being increasingly used. Yet, age, source, and donor type are important outcome factors. We have recently performed a nationwide cohort study of all patients with AA in Sweden diagnosed from 2000 to 2011 now present data on SCT patients. In total, 68 underwent SCT, 63% them had failed immunosuppressive therapy. found that, median follow-up 109 months (range, 35 192 months), 5-year overall survival...
We conducted a randomized phase III trial to compare the efficacy and safety of two purine analogs, cladribine fludarabine, with high-dose chlorambucil, in patients previously untreated chronic lymphocytic leukemia (CLL). Between 1997 2004, 223 CLL were randomly assigned cladribine, fludarabine or for six cycles therapy frequent health-related quality life assessments. There was no statistical difference primary endpoint overall response (70%), (67%) chlorambucil (59%), complete remission...